PineBridge Investments’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.71M Sell
5,840
-1,222
-17% -$402K 0.01% 324
2025
Q4
$2.48M Sell
7,062
-4,615
-40% -$1.56M 0.02% 319
2025
Q3
$3.77M Buy
+11,677
New +$3.63M 0.03% 309
2025
Q2
Sell
-14,849
Closed -$6.46M 613
2025
Q1
$6.46M Buy
14,849
+2,393
+19% +$961K 0.05% 285
2024
Q4
$4.6M Sell
12,456
-15,027
-55% -$6.29M 0.03% 322
2024
Q3
$14.3M Buy
27,483
+156
+0.6% +$83.3K 0.11% 186
2024
Q2
$14.8M Sell
27,327
-21,235
-44% -$11.2M 0.12% 182
2024
Q1
$25.2M Sell
48,562
-16,912
-26% -$8.41M 0.2% 117
2023
Q4
$30.9M Sell
65,474
-41,340
-39% -$19.1M 0.29% 78
2023
Q3
$46.5M Buy
106,814
+17,296
+19% +$7.85M 0.52% 36
2023
Q2
$39.8M Buy
89,518
+4,018
+5% +$1.85M 0.43% 55
2023
Q1
$39.3M Sell
85,500
-3,894
-4% -$1.85M 0.44% 54
2022
Q4
$45.9M Sell
89,394
-4,448
-5% -$2.26M 0.56% 42
2022
Q3
$42.6M Buy
93,842
+18,429
+24% +$8.82M 0.55% 38
2022
Q2
$36.4M Buy
75,413
+1,385
+2% +$685K 0.46% 50
2022
Q1
$36.4M Sell
74,028
-6,914
-9% -$3.16M 0.39% 53
2021
Q4
$37.5M Sell
80,942
-3,575
-4% -$1.5M 0.38% 46
2021
Q3
$31.5M Sell
84,517
-18,509
-18% -$7.03M 0.38% 62
2021
Q2
$39.3M Buy
103,026
+62,607
+155% +$23.9M 0.46% 44
2021
Q1
$14.5M Buy
40,419
+1,926
+5% +$619K 0.19% 138
2020
Q4
$12.4M Sell
38,493
-19,069
-33% -$5.85M 0.19% 135
2020
Q3
$15.5M Buy
57,562
+5,830
+11% +$1.57M 0.27% 92
2020
Q2
$13.6M Sell
51,732
-8,726
-14% -$2.33M 0.26% 96
2020
Q1
$13.7M Sell
60,458
-19,426
-24% -$5.29M 0.32% 74
2019
Q4
$24.1M Buy
79,884
+4,915
+7% +$1.35M 0.37% 67
2019
Q3
$18M Buy
74,969
+60,812
+430% +$16.7M 0.29% 95
2019
Q2
$4M Buy
+14,157
New +$3.87M 0.06% 267
2018
Q4
Sell
-370
Closed -$101K 1083
2018
Q3
$101K Sell
370
-22,553
-98% -$5.85M ﹤0.01% 912
2018
Q2
$5.46M Sell
22,923
-30,797
-57% -$7.13M 0.13% 171
2018
Q1
$11.8M Buy
53,720
+8,288
+18% +$1.95M 0.28% 106
2017
Q4
$10.2M Sell
45,432
-5,410
-11% -$1.15M 0.26% 106
2017
Q3
$9.65M Buy
50,842
+11,332
+29% +$2.16M 0.23% 114
2017
Q2
$7.43M Buy
39,510
+36,450
+1,191% +$6.55M 0.19% 127
2017
Q1
$506K Sell
3,060
-1,196
-28% -$190K 0.01% 649
2016
Q4
$612K Sell
4,256
-71,449
-94% -$9.57M 0.02% 576
2016
Q3
$9.49M Sell
75,705
-25,410
-25% -$3.28M 0.42% 83
2016
Q2
$13.3M Buy
101,115
+12,051
+14% +$1.65M 0.68% 43
2016
Q1
$12.4M Sell
89,064
-18,444
-17% -$2.46M 0.64% 48
2015
Q4
$15M Buy
107,508
+1,260
+1% +$174K 0.65% 46
2015
Q3
$14.9M Buy
106,248
+4,081
+4% +$613K 0.63% 49
2015
Q2
$16.8M Sell
102,167
-55,419
-35% -$8.85M 0.66% 45
2015
Q1
$24.3M Sell
157,586
-2,257
-1% -$321K 0.9% 23
2014
Q4
$20.1M Buy
159,843
+31,828
+25% +$3.93M 0.76% 28
2014
Q3
$15.3M Buy
128,015
+97,507
+320% +$11.2M 0.63% 36
2014
Q2
$3.28M Sell
30,508
-131,704
-81% -$13.6M 0.13% 164
2014
Q1
$16.1M Buy
162,212
+65,590
+68% +$5.93M 0.53% 56
2013
Q4
$8.93M Buy
96,622
+96,162
+20,905% +$8.54M 0.27% 112
2013
Q3
$38K Sell
460
-10,780
-96% -$924K ﹤0.01% 973
2013
Q2
$920K Buy
+11,240
New +$841K 0.03% 327

Other funds holding ELV

PineBridge Investments's ELV Position: Q1 2026 in Review

PineBridge Investments reduced its Elevance Health (ELV) stake by 17% in Q1 2026, selling an estimated $402K and leaving 5,840 shares worth $1.71M. The position accounts for 0.01% of the portfolio, ranked #324.

PineBridge Investments first reported a position in ELV in Q2 2013 and has held it in 49 quarters since. The position peaked at $46.5M in Q3 2023. 1,462 funds tracked by Wall St. Rank hold ELV as of Q1 2026.

  • PineBridge Investments held 5,840 shares of Elevance Health worth $1.71M as of Q1 2026.
  • PineBridge Investments sold 1,222 Elevance Health shares in Q1 2026, an estimated $402K.
  • Elevance Health made up 0.01% of PineBridge Investments's portfolio in Q1 2026, its #324 holding.
  • PineBridge Investments first reported a position in Elevance Health in Q2 2013 and has held it in 49 quarters since.
  • PineBridge Investments's Elevance Health position peaked at $46.5M in Q3 2023.
  • 1,462 funds tracked by Wall St. Rank held Elevance Health as of Q1 2026.

Based on PineBridge Investments's 13F filing for Q1 2026, filed 14 May 2026.